ruxolitinib for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
Cao		RCT	ruxolitinib	vitamin C	COVID-19 severe or critically	some concern	21/21	suggested	suggested 4.5-fold increase in radiologic improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
DEVENT unpublished NCT04377620		RCT	ruxolitinib	placebo	COVID-19 severe or critically	NA	-/-	suggested	suggested 53 % decrease in deaths

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis